Your body depends on glucose for energy. When you eat, your digestive system breaks carbohydrates into glucose, which then enters your bloodstream. If blood glucose stays high for too long, it damages blood vessels, nerves, and organs.
GLP-1 (glucagon-like peptide-1) is a hormone made in the small intestine right after a meal. It signals the pancreas to release insulin, helps cells absorb glucose, slows down how quickly food leaves the stomach, and sends signals to the brain to reduce appetite.
The problem? Native GLP-1 is degraded in under 2 minutes by the enzyme DPP-4. GLP-1 agonists resist this breakdown, staying active for hours. The result? Steadier blood sugar and reduced food intake, two key targets in type 2 diabetes and obesity treatment.
Table of Contents
Discovery and Early Research
Let’s rewind to the 1960s and 1970s—an era of bell-bottoms, disco lights, and labs filled with clunky glass equipment and cigarette smoke. Amid the vinyl records and typewriters, scientists were puzzling over a strange quirk in human biology called the incretin effect.
The observation was simple but baffling. Give someone a sugary drink and their pancreas floods the bloodstream with insulin. Give them the same amount of sugar through an intravenous drip, bypassing the gut entirely, and the insulin surge is only a fraction as strong. Same sugar, same dose, wildly different results.
The gut, it turned out, wasn’t just a passive tube for digestion. It was an active player, releasing chemical messengers—incretins—that acted like advanced scouts, warning the pancreas: “Food’s on the way, get the insulin ready.”
By the mid-70s, researchers had narrowed the suspects down to two main hormones:
- GIP (glucose-dependent insulinotropic polypeptide)
- GLP-1 (glucagon-like peptide-1), destined to become the star
Fast forward to the 1980s. New peptide sequencing tools let scientists map proteins with precision. GLP-1’s blueprint was finally decoded: it was not an independent molecule, but a fragment snipped from a larger protein called proglucagon. The manufacturing site? Specialized L-cells scattered along the lining of the small intestine, primed to release GLP-1 into the bloodstream the moment food arrives.
What made GLP-1 so special was its built-in safety mechanism; it only triggered insulin release when glucose was already present in the blood. That meant no dangerous sugar crashes, a common problem with some older diabetes drugs.
When scientists tested GLP-1 in both animals and humans, the results were a double revelation. Blood sugar levels dropped, but so did appetite. Meals felt more filling, and hunger faded sooner. In one molecule, they’d found a way to address two of the biggest challenges in metabolic health: high blood sugar and excess weight.
Challenges in Therapeutic Use
Using your body’s natural GLP-1 as a drug is pointless because it vanishes too fast. Native GLP-1 survives only about two minutes before an enzyme called DPP-4 shreds it like paper in a hungry shredder. Inject it, and by the time you pull the needle out, half of it’s already gone.
Scientists knew this wouldn’t work for real-world treatment, correctly assuming patients wouldn’t want to inject themselves every two minutes for the rest of their lives. So, researchers had to figure out how to keep GLP-1 around longer. They tried a few tricks:
- DPP-4-resistant versions: tweaking the GLP-1 molecule so DPP-4 can’t “see” where to cut it
- Fatty acid tails: causing the GLP-1 to latch onto albumin in your blood, hiding from DPP-4
- Encapsulation: wrapping the molecule in protective coatings so it survives longer before being exposed to enzymes
These hacks meant the drug could hang out in the bloodstream for hours, or even days, instead of minutes.
Once they cracked the problem, scientists got creative. They started making synthetic analogs, lab-built versions that work like GLP-1 but don’t break down so fast. Some, like liraglutide, had chemical tweaks and those fatty acid chains that made them stick to albumin.
Over time, these analogs evolved from twice-a-day injections to once-a-week shots, a massive leap for patient convenience. And now, they’re even making oral versions like semaglutide (Rybelsus®) by pairing the drug with special absorption enhancers so it can survive your stomach acid long enough to do its job.
First-Generation GLP-1 Agonists
Meet the Gila monster, a chunky, slow-moving lizard found in the southwestern US and northern Mexico. It doesn’t look like a medical miracle, but in its saliva lives exendin-4, a peptide very similar to human GLP-1 but much harder for DPP-4 to destroy.[1]
Pharmaceutical scientists saw a treatment opportunity . . . and dollar signs. They copied exendin-4 in the lab, made a few chemical tweaks so it would be safe for humans, and called the drug exenatide. In 2005, the US Food and Drug Administration gave it the green light under the brand name Byetta®, making it the very first GLP-1 receptor agonist approved for type 2 diabetes.[2]
Here’s how it worked in real life:
- Dosing: You used a pen injector to give yourself a shot twice a day, about an hour before breakfast and dinner.
- Mechanism: Once in your system, exenatide acts like GLP-1, triggering insulin release when your blood sugar is high, slowing down your stomach emptying and nudging your brain to feel full sooner.
- Results from trials: People on Byetta saw their HbA1c (a 3-month average of blood sugar) drop by roughly 0.5%–1%. They often lost 2–3 kilograms of body weight without even trying. Most importantly, they avoided the dangerous sugar crashes that came with older diabetes drugs like sulfonylureas.
But it wasn’t perfect. Many patients felt nauseous in the first few weeks, and some had vomiting or diarrhea. For most people, these effects were temporary, and their bodies adjusted over time.
The verdict from patients? Even with the twice-daily needles and the initial queasiness, it was worth it. For the first time, they could manage their diabetes without constant finger-prick panic, their blood sugar swinging like a pendulum.
Byetta proved you could hack the body’s natural GLP-1 system, make it last longer, and give people a safer, steadier way to control type 2 diabetes. And it all started with the spit of a desert lizard.
Evolution of Longer-Acting Formulations
Once the chemistry was established, the next mission scientists faced was to make GLP-1 agonists last longer in the body, so patients wouldn’t have to keep poking themselves like a pincushion.
Liraglutide (Victoza) | FDA Approved 2010
In 2010, liraglutide strolled onto the scene. Researchers attached a fatty acid chain to the molecule, allowing it to bind to albumin, a protein that circulates in the bloodstream. This modification slows the drug’s breakdown by enzymes, extending how long it stays active in the body.
The result was that instead of two injections a day, patients needed only one.
Once-Weekly GLP-1 Agonists
And then came the real mic drop: once-weekly injections. Suddenly, you could forget about your meds for six days straight and still be on track.
First up was Bydureon® (extended-release exenatide), which used teeny-tiny biodegradable microspheres that slowly leaked the drug into your system over a whole week, like a slow-drip coffee maker for your pancreas.
Next, dulaglutide (Trulicity®) arrived in a prefilled, ready-to-use pen that required zero mixing, zero complicated prep, you basically click, inject, and go about your day.
Finally, semaglutide (Ozempic®, also Rybelsus in pill form) took potency to the next level. Highly effective, still weekly, and with results that made headlines, it became the celebrity of the GLP-1 world. With fewer injections, people were way more likely to stick to their treatment plans.
Now GLP-1s are one of the most popular weight loss drugs on the market, with hundreds of telehealth clinics providing it.
If you’ve been wondering how these therapies might fit into your own health journey, there’s no need to guess.
GLP-1 Agonists in Obesity Treatment
For years, GLP-1 drugs sat in the diabetes aisle, quietly helping patients control blood sugar. Then came semaglutide, and it didn’t just step into the obesity arena, it tore the doors off. When researchers tested it at higher doses, the results were jaw-dropping.
Patients didn’t just lose a couple of stubborn pounds; they shed an average of 15% of their total body weight. For perspective, older obesity drugs only saw a 5% drop.
In 2021, the FDA stamped its approval on high-dose semaglutide under the brand name Wegovy®, officially giving doctors a new heavyweight contender for chronic weight management.
Wegovy works in two clever ways: it slows how quickly your stomach empties, making large portions feel impossible, and it sends chemical signals straight to the brain’s appetite command center, quieting the constant mental chatter about food.[3]
For many, this was the game-changer, obesity treatment was no longer framed as a moral struggle of “willpower versus cake.” It became a science-backed recalibration of the body’s hunger systems.
Cardiovascular and Renal Benefits
The GLP-1 story didn’t end with smaller waistlines. In the late 2000s, still haunted by the fallout from drugs like rosiglitazone (brand name Avandia®), linked to increased heart attack risk, the FDA laid down a blunt new rule: every new diabetes drug must prove it won’t harm the heart before it ever sees pharmacy shelves. That single mandate unleashed a wave of massive cardiovascular outcomes trials, some lasting five years and enrolling more than 10,000 patients each.
The findings went beyond anyone’s cautious hopes.
- LEADER (liraglutide): In the LEADER trial, liraglutide lowered major cardiovascular events by 31% and all-cause mortality by 26% in type 2 diabetes patients with chronic kidney disease, compared with placebo.[4]
- SUSTAIN-6 (semaglutide): In 3,297 high-risk patients with type 2 diabetes, once-weekly semaglutide reduced major cardiovascular events by 26% and stroke by 39% over two years.[5]
- REWIND (dulaglutide): In 9,901 adults with type 2 diabetes, weekly dulaglutide reduced major cardiovascular events by 12% over 5.4 years, benefiting participants with or without prior heart disease.[6]
Meanwhile, the kidneys were quietly rewriting their own chapter. In post-hoc analyses and dedicated renal endpoints, GLP-1 drugs slowed the decline of kidney function, reduced new cases of macroalbuminuria (a marker of kidney damage), and hinted at delaying the need for dialysis in diabetic patients. For clinicians used to watching kidney disease march forward despite treatment, these results were a massive shift.
What began as a quest to control blood sugar had, almost unexpectedly, produced drugs that act like bodyguards for the heart and kidneys, two of the most fragile and essential organs in chronic disease.
Recent Advances and Next-Generation Therapies
In 2019, the impossible happened: a fragile, easily destroyed protein was turned into a pill. Oral semaglutide, branded as Rybelsus, wasn’t just a new drug, it was a pharmaceutical daredevil stunt.
Normally, proteins like this get torn apart by the acidic chaos of the stomach before they ever have a chance to work. But scientists slipped it past nature’s defenses by pairing it with an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate).[7]
The catch? You have to play by its strict rules. Take it first thing in the morning, with no more than four ounces of water, and then stand in breakfast purgatory for 30 minutes before eating or drinking anything else. One sip too many or a premature bite of toast, and the magic might fail.
Just three years later, in 2022, the game shifted again with tirzepatide (Mounjaro®). This wasn’t just a GLP-1 agonist; it was a two-pronged metabolic strike team, stimulating both GLP-1 and GIP receptors. Instead of coaxing the body down one hormonal pathway, it sent simultaneous “control appetite, lower glucose” commands through two different channels. The results stunned researchers: in trials, people lost up to 22.5% of their body weight, figures that made even semaglutide look modest. Researchers have also begun investigating its potential for specific populations, including those dealing with tirzepatide for PTSD-related weight gain, where medication-induced metabolic changes make weight management particularly challenging.
When tirzepatide earned FDA approval for obesity under the brand name Zepbound®, it marked the first dual-action GLP-1/GIP therapy officially recognized for chronic weight management. It quickly became one of the most sought-after prescriptions in metabolic medicine, praised for its impressive efficacy and once-weekly dosing convenience.
Now, whispers in research labs are about triple agonists, single injections that stimulate GLP-1, GIP, and glucagon receptors all at once. The idea is to suppress hunger, improve blood sugar, and rev up calorie burning, attacking obesity and type 2 diabetes from every known hormonal angle. Early-stage data hint that the next wave could push weight loss into territory once only achievable with bariatric surgery.
Societal and Economic Impact
In less than five years, GLP-1-based drugs have leapt from obscure endocrinology clinics to the front pages of celebrity magazines. Pharmacies in New York, London, and Sydney now run months-long waiting lists.
Hollywood publicists speak in euphemisms about “metabolic resets,” while gossip columns compare red-carpet photos like crime-scene evidence. On TikTok, the term “Ozempic face”—the hollowed cheeks some users develop after rapid weight loss—racks up millions of views under a trending hashtag.
But the glamour has a hard edge. In the US, a single month’s supply without insurance costs $900–$1,300, more than the median monthly rent in dozens of states. In France and Japan, national health systems will sometimes cover the drugs for patients with advanced type 2 diabetes or severe obesity, but those with milder conditions must pay out of pocket.
In many low- and middle-income countries, the cost can exceed an average worker’s annual income. And because both obesity and diabetes are chronic conditions, stopping the medication often reverses the gains, sending weight and blood sugar creeping back.[8]
The conversation is no longer about whether these drugs work, clinical trials have settled that, but about who should have access. Should someone who wants to shed 15 vanity pounds be prioritized the same as a patient whose diabetes is damaging their kidneys?
Public health experts caution that the decision will hinge not just on medical data, but also on political will, the structure of national insurance systems, and uncomfortable questions about global equity.
You deserve care that feels made for you, not care that leaves you guessing. Ready for a personal plan?
Finding a GLP-1 provider that’s safe and affordable is key.
Timeline of Regulatory Milestones
- 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections
- 2010: Liraglutide (Victoza®): Longer-lasting, once-daily injection
- 2014: Dulaglutide (Trulicity): Once-weekly injection arrives
- 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects
- 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomach’s defenses
- 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment
- 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes
- 2023: Tirzepatide (Zepbound®): Expanded approval for obesity
- 2023–2024: Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability
The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts. FDA responded by keeping these injectables on its drug-shortage list, which gives compounding pharmacies a narrow, but legal, window to prepare patient-specific versions until manufacturers catch up.
Conclusion
From a weird gut hormone that lasted two minutes to blockbuster drugs changing how we treat diabetes, obesity, heart disease, and maybe more, the journey of GLP-1 agonists has been nothing short of remarkable.
This isn’t the end. Next-gen multi-agonists, oral versions, and even weight-loss + metabolic combo drugs are on the horizon. Science is moving fast, and if the past 20 years are anything to go by, we haven’t seen the full potential yet.
FAQs
What is the history of GLP-1 agonist drugs?
The history of GLP-1 agonist drugs began in the 1960s–80s. In 2005, the first drug, exenatide, derived from Gila monster saliva, hit the market. This breakthrough paved the way for longer-lasting versions, including once-weekly injections and oral semaglutide tablets, transforming diabetes and obesity treatment.
How was the GLP-1 agonist discovered?
GLP-1 was discovered when, while studying the “incretin effect,” scientists noticed certain gut hormones spurred insulin release after meals. They found a peptide in Gila monster saliva, exendin-4, that mimicked human GLP-1 but resisted breakdown. By tweaking its structure, they created stable drugs that boosted insulin while lowering blood sugar.
When was the GLP-1 hormone discovered?
The GLP-1 hormone was discovered in the 1980s. Researchers identified GLP-1 as a fragment of the proglucagon gene expressed in intestinal L-cells. They mapped its amino acid sequence, confirmed its role in stimulating insulin after meals, and found it degraded quickly, spurring the search for longer-lasting synthetic versions.
How long have GLP-1 drugs been on the market?
GLP-1 agonists were on the market in 2005 with exenatide. Since then, new generations, like liraglutide in 2010, once-weekly dulaglutide in 2014, and oral semaglutide in 2019, have arrived roughly every few years, each improving convenience, potency, and durability.
Sources
- Deane, A. M., Chapman, M. J., & Horowitz, M. (2010). The therapeutic potential of a venomous lizard: The use of glucagon-like peptide-1 analogues in the critically ill. Critical Care, 14(5), 1004. https://doi.org/10.1186/cc9281
- Latif, W., Lambrinos, K. J., & Rodriguez, R. (2021). Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls. https://pubmed.ncbi.nlm.nih.gov/34283517/
- Palana, C., Aburumman, A., Kachungunu, C. N. K., Hocquard, A., Avila, G., Pagana, A., Chen, A., & John, T. (2024). Analyzing the effects of semaglutide (Ozempic/Wegovy) on metabolism: Investigating correlations with weight reduction. Journal of Positive Psychology and Wellbeing, 8(4), 19–41. https://core.ac.uk/download/pdf/616775745.pdf
- Mann, J. F., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & LEADER Publication Committee on behalf of the LEADER Trial Investigators. (2018). Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: Results from the LEADER trial. Circulation, 138(25), 2908–2918. https://doi.org/10.1161/CIRCULATIONAHA.118.036418
- Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., & Woo, V. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
- Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., & Xavier, D. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
- Solis-Herrera, C., Kane, M. P., & Triplitt, C. (2024). Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: The oral semaglutide experience. Clinical Diabetes, 42(1), 74–86. https://doi.org/10.2337/cd22-0118
- Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Cartwright, B. G., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025). Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Network Open, 8(1), e2457349. https://doi.org/10.1001/jamanetworkopen.2024.57349